Mitoxantrone liposomal - CSPC ZhongQi Pharmaceutical Technology Co.

Drug Profile

Mitoxantrone liposomal - CSPC ZhongQi Pharmaceutical Technology Co.

Alternative Names: 2010L04017; Mitoxantrone hydrochloride liposome injection

Latest Information Update: 05 Jun 2017

Price : $50

At a glance

  • Originator CSPC ZhongQi Pharmaceutical Technology
  • Class Anthraquinones; Antineoplastics
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Peripheral T-cell lymphoma
  • Phase I/II Non-Hodgkin's lymphoma
  • No development reported Solid tumours

Most Recent Events

  • 23 May 2017 CSPC ZhongQi Pharmaceutical Technology terminates a phase-II trial in Cutaneous T-cell lymphoma (Second-line therapy or greater) in China (IV) (NCT02597153)
  • 22 May 2017 CSPC ZhongQi Pharmaceutical Technology withdraws prior to enrolment a phase-I trial in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater, Late-stage disease) in China (IV) (NCT02595242)
  • 02 Aug 2016 CSPC ZhongQi Pharmaceutical Technology plans a phase I/II trial in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (NCT02856685)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top